CSL, Pinnacle, and Telix Shares: Buy, Hold, or Sell?
Investors seeking to navigate the Australian Securities Exchange (ASX) have three notable companies to consider: CSL Limited, Pinnacle Investment Management Group Ltd, and Telix Pharmaceuticals Ltd. Analysts are weighing in on whether these stocks are advisable for buying, holding, or selling.
CSL Limited: Buy, Hold, or Sell?
CSL Limited’s shares are under scrutiny amid recent analyst evaluations. Morgans has issued a buy rating, assessing the shares as undervalued with a target price of $249.51. Analysts highlight that current valuations do not reflect the true potential of CSL.
Despite an overall business trajectory aligning with expectations, the company recently downgraded its fiscal year 2026 guidance by 2-3% concerning both revenue and NPATA mid-points. This adjustment stems largely from declining US influenza vaccination rates and cost-containment measures affecting albumin demand in China. Management is optimistic about mitigating these impacts in the first half of fiscal 2026.
Pinnacle Investment Management Group: A Buying Opportunity
Pinnacle Investment Management Group has experienced a significant drop in its share price recently. Morgans has responded by upgrading its rating to buy, with a revised target price of $23.21.
The firm’s first-half results for fiscal 2026 revealed a net profit after tax (NPAT) of approximately A$67 million, representing an 11% decline compared to the previous year. However, analysts argue that, excluding one-time impacts, the underlying performance was more robust than suggested by the headline figures.
- Fiscal Year 2026 Net Profit After Tax (NPAT): A$67 million
- Target Price: A$23.21 (down from A$26.30)
- Fiscal Year 2027 Earnings Per Share (EPS) forecast: increased by 8%
Telix Pharmaceuticals: Buy Rating and Future Prospects
Telix Pharmaceuticals has faced a challenging year, seeing its shares decline. Nevertheless, Bell Potter sees this as a prime buying opportunity, setting a buy rating and a target price of $23.00.
Looking forward, analysts expect a significant turnaround for Telix in fiscal 2026, with hopes pinned on the approval of Zircaix following a resubmitted Biological License Application. The FDA had previously rejected the application but not based on safety or efficacy concerns. The market potential for Zircaix could exceed US$500 million once approved.
- Target Price: $23.00
- Expected Market for Zircaix: >US$500 million
- Expansion of Iluccix/Gozellix sales in the PSMA franchise
Conclusion
In summary, CSL Limited, Pinnacle Investment Management Group, and Telix Pharmaceuticals present varied investment opportunities. Analysts recommend evaluating these stocks closely, given their distinct valuations and market potential. For more detailed investment insights, keep visiting Filmogaz.com.
